Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge advises on the sale of RK Projektledning to Qflow

Vinge has advised the sellers in connection with the sale of all shares in RK Projektledning AB to Qflow Group.
December 05, 2025

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest land in Latvia and Lithuania

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of a Latvian and a Lithuanian company from Dasos Timberland Fund II (a fund managed by CapMan Natural Capital).
December 05, 2025

Vinge advises and Valcon in connection with the acquisition of Bricobomba

Bricobomba AB is a Swedish company with expertise in data and AI. The acquisition will strengthen Valcon’s capacity in the Nordic region and further expand the company’s ability to deliver comprehensive data and AI-based services to its customers on a pan-European scale.
December 05, 2025